Suppliers and packagers for generic pharmaceutical drug: LAMIVUDINE; ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857	NDA	ViiV Healthcare Company	49702-202-18	60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18)	2010-10-19
Aurobindo Pharma	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	077558	ANDA	Aurobindo Pharma Limited	65862-036-10	6 BLISTER PACK in 1 CARTON (65862-036-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK	2017-05-05
Aurobindo Pharma	LAMIVUDINE AND ZIDOVUDINE	lamivudine; zidovudine	TABLET;ORAL	077558	ANDA	Aurobindo Pharma Limited	65862-036-60	60 TABLET, FILM COATED in 1 BOTTLE (65862-036-60)	2017-05-05

Lamivudine; Zidovudine API Suppliers Analysis

Last updated: February 19, 2026

This report analyzes key suppliers of Lamivudine and Zidovudine Active Pharmaceutical Ingredients (APIs). It identifies major manufacturers, production capacities, and regulatory compliance, providing critical data for supply chain assessment and strategic sourcing.

Who are the leading global suppliers of Lamivudine API?

Major global suppliers of Lamivudine API include companies with established manufacturing infrastructure and broad market reach. These suppliers are often characterized by significant production volumes and adherence to stringent quality control standards.

Key suppliers for Lamivudine API include:

• Gland Pharma Limited: An Indian pharmaceutical company known for its finished dosage forms and API manufacturing capabilities. Gland Pharma has a history of supplying various antiretroviral APIs.
• Hetero Drugs Limited: Another prominent Indian pharmaceutical manufacturer with a substantial API production base. Hetero is a significant player in the global generics market, including antiretrovirals.
• Mylan N.V. (now Viatris): While Viatris is a consolidated entity, its legacy operations, particularly those of Mylan, have been significant suppliers of antiretroviral APIs, including Lamivudine.
• Cipla Limited: An Indian multinational pharmaceutical company with extensive API manufacturing facilities. Cipla has been a long-standing supplier of essential medicines, including those for HIV treatment.
• Emcure Pharmaceuticals: An Indian biopharmaceutical company with API manufacturing and marketing operations, contributing to the global supply of various drug substances.

These suppliers typically operate multiple manufacturing sites, often located in India and other regions with robust chemical manufacturing sectors. Production capacities for Lamivudine API can vary but are generally in the multi-ton range annually to meet global demand. Regulatory compliance is a critical factor, with these suppliers holding accreditations from major health authorities like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others.

Who are the leading global suppliers of Zidovudine API?

The landscape for Zidovudine API suppliers is similar to that of Lamivudine, with a strong presence of Indian pharmaceutical manufacturers. These companies leverage their expertise in complex chemical synthesis and large-scale production.

Key suppliers for Zidovudine API include:

• Hetero Drugs Limited: As with Lamivudine, Hetero Drugs is a significant producer of Zidovudine API, catering to both domestic and international markets.
• Gland Pharma Limited: Gland Pharma also lists Zidovudine among its API offerings, contributing to its broad portfolio of antiretroviral intermediates and APIs.
• Cipla Limited: Cipla's API division is a consistent supplier of Zidovudine, supporting its commitment to making HIV/AIDS treatment accessible.
• Emcure Pharmaceuticals: Emcure contributes to the Zidovudine API supply chain, aligning with its focus on therapeutic areas like infectious diseases.
• Aurobindo Pharma Limited: A major Indian pharmaceutical company with substantial API manufacturing capabilities. Aurobindo is a key player in the generics market and a significant supplier of antiretroviral APIs.

These suppliers are characterized by their investment in research and development for process optimization and their commitment to Good Manufacturing Practices (GMP). Production facilities are typically located in India, with some potentially having secondary sites in other regulated or semi-regulated markets. Annual production capacities for Zidovudine API are substantial, reflecting its status as a foundational antiretroviral drug. Regulatory approvals from bodies like the FDA and EMA are standard for these suppliers to participate in global pharmaceutical markets.

What are the regulatory compliance standards for these APIs?

Suppliers of Lamivudine and Zidovudine APIs must adhere to stringent regulatory compliance standards to ensure product quality, safety, and efficacy. These standards are primarily dictated by major international health authorities.

Key regulatory compliance aspects include:

• Current Good Manufacturing Practices (cGMP): Manufacturers must operate under cGMP guidelines as defined by regulatory bodies. This covers all aspects of production, including facility design, equipment, personnel, raw material control, process validation, documentation, and quality control. The FDA's 21 CFR Parts 210 and 211, and the European Union's EudraLex Volume 4, are primary references.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies like the FDA. A DMF provides detailed information about the manufacturing process, facilities, and controls for an API. This allows regulatory agencies to review the API information in support of a drug product application without disclosing proprietary details to the drug product manufacturer.
• Certificates of Suitability (CEPs): For the European market, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that an API complies with the requirements of the relevant European Pharmacopoeia monograph.
• Inspections and Audits: API facilities are subject to regular inspections by regulatory authorities (e.g., FDA, EMA) and customer audits. Successful outcomes from these inspections are critical for continued market access.
• Pharmacopoeial Compliance: APIs must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define the identity, strength, quality, and purity of drug substances.
• Impurity Profiling and Control: Rigorous control and characterization of impurities are paramount. Suppliers must demonstrate that their manufacturing processes consistently control process-related impurities, degradation products, and residual solvents within acceptable limits, often guided by ICH Q3A, Q3C, and Q3D guidelines.

Companies that consistently meet these standards are recognized for their reliability and quality. For example, a supplier with an FDA-approved DMF and a recent successful FDA inspection is generally considered a low-risk partner. Similarly, a CEP from EDQM is a strong indicator of compliance for European Union markets.

What is the typical production process for Lamivudine and Zidovudine?

The production of Lamivudine and Zidovudine APIs involves multi-step organic synthesis processes. While specific proprietary details vary between manufacturers, the general chemical pathways are well-established.

Lamivudine Synthesis:

Lamivudine (3'-deoxy-3'-thiacytidine) is a nucleoside reverse transcriptase inhibitor (NRTI). Its synthesis typically involves building the thiacytidine ring system and attaching the appropriate base.

A common synthetic approach often starts with:

1. Chiral Starting Material: Using a chiral precursor, such as a derivative of L-ribose or a related carbohydrate.
2. Formation of the Thiacyclopentane Ring: Incorporating sulfur into the ring structure. This can involve reactions with thiols or sulfur-donating reagents.
3. Glycosidic Bond Formation: Coupling the synthesized sugar moiety with the cytosine base. This is a critical step that requires precise control to achieve the correct stereochemistry. Protecting groups are often employed on the base and sugar.
4. Deprotection and Purification: Removal of any protecting groups and rigorous purification steps, often involving crystallization or chromatography, to achieve the required API purity.

The stereochemistry at the chiral centers is crucial for Lamivudine's activity. Manufacturers must ensure high enantiomeric purity.

Zidovudine Synthesis:

Zidovudine (3'-azido-3'-deoxythymidine) is also an NRTI. Its synthesis involves incorporating an azido group at the 3' position of a thymidine analog.

A typical synthetic pathway for Zidovudine includes:

1. Starting Material: Often begins with thymidine or a protected derivative.
2. Functionalization at the 3' Position: This is a key step. A common method involves converting the 3'-hydroxyl group of thymidine into a leaving group (e.g., tosylate, mesylate).
3. Nucleophilic Substitution with Azide: The leaving group is then displaced by an azide anion (N3-), introducing the azido group. This reaction typically proceeds with inversion of stereochemistry, which is necessary for Zidovudine.
4. Deprotection and Purification: If protecting groups were used, they are removed. The crude Zidovudine is then purified, typically through crystallization, to meet pharmacopoeial standards.

Both processes require specialized chemical reactors, precise temperature and pressure control, and careful handling of reagents, some of which can be hazardous. Quality control checkpoints are integrated throughout the synthesis to monitor reaction completion, intermediate purity, and final API specifications.

What are the market dynamics and competitive landscape for these APIs?

The market for Lamivudine and Zidovudine APIs is characterized by established demand driven by their use in fixed-dose combination (FDC) antiretroviral therapies for HIV/AIDS. The competitive landscape is mature, with a significant number of manufacturers, primarily based in India.

Market Dynamics:

• Demand Stability: Demand is relatively stable, though it can be influenced by global HIV/AIDS treatment guidelines, public health initiatives, and the availability of newer antiretroviral drugs.
• Price Sensitivity: As these are often used in essential medicines, particularly in lower and middle-income countries, price is a critical factor. This leads to intense price competition among API manufacturers.
• Generic Dominance: The market is dominated by generic API manufacturers, as both Lamivudine and Zidovudine are off-patent.
• FDC Integration: A significant portion of API production is for use in FDCs, such as Lamivudine/Zidovudine combinations, or in triple-drug regimens. Manufacturers often supply both APIs to facilitate this.
• Regulatory Hurdles: Entering and remaining in the market requires continuous investment in regulatory compliance and quality assurance, creating a barrier to entry for new, non-compliant players.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Pharmaceutical companies seek to diversify their supplier base to mitigate risks.

Competitive Landscape:

• Concentration of Indian Manufacturers: India is the dominant manufacturing hub for these APIs, with companies like Hetero Drugs, Gland Pharma, Cipla, Aurobindo Pharma, and Emcure Pharmaceuticals holding significant market share.
• Global Reach: While manufacturing is concentrated, these companies export their APIs globally, serving major pharmaceutical companies in North America, Europe, Asia, and Africa.
• Cost Competitiveness: Indian manufacturers often benefit from lower manufacturing costs, skilled labor, and a well-developed chemical industry infrastructure, allowing them to offer competitive pricing.
• Quality and Compliance as Differentiators: While price is important, quality and regulatory compliance are paramount. Suppliers with strong regulatory track records (FDA, EMA approvals) have a competitive advantage.
• Strategic Partnerships: API suppliers often form strategic partnerships with finished dosage form manufacturers, providing a reliable supply chain for critical HIV medications.
• Emerging Players: While the market is mature, there can be consolidation among existing players or the emergence of new capacities from established companies looking to expand their API portfolios.

The competitive environment necessitates efficient production processes, robust quality management systems, and a strong understanding of global regulatory requirements.

What are the key considerations for sourcing Lamivudine and Zidovudine APIs?

Sourcing Lamivudine and Zidovudine APIs requires a thorough evaluation of several factors to ensure a reliable, high-quality, and compliant supply chain.

Key sourcing considerations include:

• Supplier Regulatory Compliance:
  • Verify current FDA, EMA, and other relevant health authority inspection statuses.
  • Review DMF filings and their status.
  • Confirm possession of CEPs where applicable for European markets.
  • Assess compliance with ICH guidelines for impurities and quality.
• Quality Management Systems:
  • Evaluate the supplier's Quality Management System (QMS) for robustness.
  • Review Quality Agreements to ensure clear responsibilities.
  • Assess batch-to-batch consistency and historical quality performance.
• Manufacturing Capabilities and Capacity:
  • Understand the supplier's production capacity and their ability to scale up.
  • Inquire about production timelines and lead times.
  • Assess the reliability and redundancy of their manufacturing sites.
• Supply Chain Security and Resilience:
  • Evaluate the supplier's raw material sourcing strategy and their supply chain visibility.
  • Understand their business continuity and disaster recovery plans.
  • Assess geographical diversification of their operations to mitigate geopolitical or environmental risks.
• Cost and Commercial Terms:
  • Obtain detailed quotations and understand pricing structures.
  • Negotiate payment terms and contract duration.
  • Consider total cost of ownership, including freight, import duties, and quality control testing.
• Technical Support and Communication:
  • Assess the supplier's responsiveness to technical queries and requests.
  • Evaluate their ability to provide necessary technical documentation.
  • Ensure effective communication channels are established.
• Auditing Capabilities:
  • Plan for and conduct site audits (remote or in-person) to verify manufacturing practices and QMS adherence.

A comprehensive sourcing strategy involves not only identifying potential suppliers but also conducting due diligence to select partners capable of consistently meeting the stringent demands of the pharmaceutical industry.

Key Takeaways

• Leading suppliers of Lamivudine and Zidovudine APIs are predominantly Indian pharmaceutical manufacturers, including Gland Pharma, Hetero Drugs, Cipla, Emcure Pharmaceuticals, and Aurobindo Pharma.
• Regulatory compliance, particularly cGMP adherence and successful inspections by authorities like the FDA and EMA, is a critical prerequisite for market access and supplier selection.
• The manufacturing processes for both APIs involve complex multi-step organic synthesis, requiring precise stereochemical control and rigorous purification.
• The API market is characterized by stable demand, intense price competition, and generic dominance, with a strong emphasis on supply chain resilience and quality assurance.
• Sourcing decisions must prioritize regulatory compliance, quality management systems, manufacturing capacity, supply chain security, and cost-effectiveness.

FAQs

1. What is the primary use of Lamivudine and Zidovudine APIs? Lamivudine and Zidovudine APIs are primarily used in the manufacturing of antiretroviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection. They are often formulated into fixed-dose combinations.

2. Are there any specific impurity concerns that buyers should monitor for these APIs? Buyers should monitor for related substances, residual solvents, and any process-specific impurities. Manufacturers must demonstrate robust control over these, often guided by ICH Q3A, Q3C, and Q3D guidelines.

3. How do fluctuations in raw material costs impact the pricing of these APIs? Fluctuations in the cost of key chemical intermediates and raw materials can directly influence the production cost and, consequently, the pricing of Lamivudine and Zidovudine APIs. Suppliers with diversified raw material sourcing and efficient process economics are better positioned to manage these fluctuations.

4. What is the typical shelf life of Lamivudine and Zidovudine APIs? The typical shelf life for these APIs, when stored under recommended conditions, is generally between two to five years. Specific details are provided by the manufacturer and are based on stability studies.

5. Can a single supplier reliably provide both Lamivudine and Zidovudine APIs? Yes, many of the major pharmaceutical companies that manufacture these APIs have the capability to produce both Lamivudine and Zidovudine. This can offer advantages in terms of supply chain integration and simplified sourcing for drug product manufacturers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs – Preliminary Identification of Potential Issues. Retrieved from https://www.fda.gov/ (Specific document retrieval requires advanced search on FDA website or a direct link, which is dynamic. Placeholder for general FDA guidance reference.)

[2] European Medicines Agency. (n.d.). EU Legislation and Guidelines for Medicines. Retrieved from https://www.ema.europa.eu/ (Specific document retrieval requires advanced search on EMA website or a direct link, which is dynamic. Placeholder for general EMA guidance reference.)

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ (Placeholder for general ICH guidelines reference. Specific ICH documents like Q3A, Q3C, Q3D would be cited individually if detailed in text.)

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/ (Placeholder for general EDQM CEP information.)

[5] United States Pharmacopeial Convention. (n.d.). USP-NF. Retrieved from https://www.usp.org/ (Placeholder for general USP-NF reference.)

[6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/ (Placeholder for general European Pharmacopoeia reference.)